Sigla Sciences delivers results through a combination of technology solutions, data-driven workflows, and expert leadership. The following case studies illustrate how our approach creates real-world impact and opens new possibilities for our clients.
Accelerating Reimbursement Readiness with a Comprehensive Toolkit
Challenge: A leading biopharma needed a coding and reimbursement toolkit to support the launch of a complex oncology therapy under accelerated approval timelines.
Solution: Using our time-tested launch workflows, we co-developed content with KOL pharmacists and physicians, used our MLR Pre-Flight program to speed review, and packaged the outputs into a comprehensive toolkit including a Billing and Coding Guide, Prior Authorization Checklist, and other resources for HCP reimbursement teams.
Impact: Delivered a five-piece toolkit on time and under budget, enabling rapid reimbursement team engagement and supporting successful early adoption.
Strengthening a Payer Value Proposition to Overcome Reimbursement Denials
Challenge: A medical device customer faced repeated payer denials due to gaps in its value proposition. Despite strong clinical evidence, payers were unconvinced of the device’s cost-effectiveness and real-world impact. The company needed to reframe its case to secure coverage and drive adoption.
Solution: Using our PayerRadar™ platform and KPI dashboards, we conducted a structured assessment of payer decision drivers, mapped gaps in the original value story, and developed a revised payer value proposition. We equipped the client with evidence-based messaging, refined economic models, and payer-ready discussion tools. Our team then supported field conversations with targeted payers, leveraging the dashboards to monitor feedback and adjust in real time.
Impact: The revised value proposition successfully shifted payer perception, resulting in reversal of key denials and expanded coverage. The KPI dashboards provided ongoing visibility into payer engagement and outcomes, enabling the client to sustain access gains and position the device for long-term market success.
Deploying an Outcomes-Based Agreement with Technology and Data Partners
A Fortune 100 pharma company tapped our team to lead the technical execution and adjudication of a Value Based Agreement. We partnered with an innovative technology team to develop dashboards and data tools to track and visualize agreement performance, automate analytics, and help the company advance their value-based pricing strategies. The project was so successful that C-suite leaders used this as a demonstration of the company's tech and market access savvy, and our team was asked to take the same technology to the company's access, brand, digital, and policy teams outside of the United States to assess the company's UK and EU-based Outcomes Based Agreement digital infrastructure needs.
Accelerating Adoption of a New Treatment Paradigm
A leading oncology biopharma needed to drive HCP acceptance for a pair of novel immuno-oncology agents, as lack of familiarity risked hesitancy and slow adoption, particularly among community oncology. We partnered with a national society to deploy unbranded, education-first, peer-to-peer content led by KOL physicians and pahrmacists. Our tailored webinars, conferences, and online educational modules for HCPs resulted in multi-company backing for the society, a sold-out inaugural meeting with more than 400 HCPs in attendance. The biopharma client credited our team for driving adoption and paving the way for their new innovation.
Landscape Search & BD/Corporate Strategy Opportunity Evaluation
A US-based team group sought opportunities in Europe. They needed a comprehensive search and custom-structured database to evaluate the most attractive opportunities according to their partnership and investment criteria. We designed a country-by-country opportunity search methodology for companies and assets, leveraging biotech hub and investment cluster data and local experts. We built profiles of companies and assets, leading to a customized analytics dashboard and toolkit for opportunity evaluation. Our results were a database of 500+ companies and 400+ assets, enabling our client to prioritize investment areas and business cases.